newsfilter
← Latest News
ACCESS Newswire·

Kadmon Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation

NEW YORK, NY / ACCESSWIRE / August 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the National Comprehensive Cancer Network® (NCCN) added REZUROCKTM (belumosudil) tablets to its NCCN Clinical Practice Guidelines in Oncology (NCCN Gui